News and Updates

The true story of how artificial pancreas systems moved from an idea to a therapy, improving the lives of millions with type 1 diabetes.

Since 2014, Alecia Wesner has participated in numerous T1D clinical trials, many of which were early artificial pancreas system trials.

Vertex announced the first stem cell-derived islet therapy is entering a phase 3 clinical trial for type 1 diabetes.

A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential to help beta cell transplants survive in people with type 1 diabetes (T1D) with fewer side effects. The first data from this Breakthrough T1D-funded study suggests it does. The study was presented at the 5th […]

At the 2024 International Society for Pediatric and Adolescent Diabetes (ISPAD) Conference in Lisbon, Portugal, the world’s leading diabetes researchers, academics, and members of industry gathered to share the latest and greatest in diabetes research. Breakthrough T1D leaders and many of our funded researchers and collaborators were on hand —for ISPAD’s 50th birthday—to share new […]

Here is Aaron J. Kowalski, Ph.D., C with the key takeaways from the conference and below is a written summary of Breakthrough T1D highlights.

A new publication provides more evidence for C-peptide as a validated surrogate to predict clinical benefits of disease-modifying therapies in T1D.

The true story of how Tzield (teplizumab), the first disease-modifying therapy approved for use in delaying type 1 diabetes (T1D) onset, made it to market.

Leading researchers gathered for the ATTD meeting, which featured more than 50 studies presented by Breakthrough T1D-funded researchers.

This year’s Advanced Technologies & Treatments for Diabetes (ATTD) meeting, which will be held on March 6-9, will have 50 Breakthrough T1D-funded presenters.